Press Release
February 2, 2022

Navitor Pharmaceuticals Announces Janssen Has Acquired Anakuria Therapeutics, Inc.

The Life Sciences team advised Navitor Pharmaceuticals, LLC on Janssen Pharmaceuticals, Inc.’s acquisition of Anakuria Therapeutics, Inc.

Navitor is the leader in the development of mTORC1-targeted therapeutics designed to help patients live longer and healthier lives.

Anakuria is a company recently formed by Navitor to advance its novel class of selective rapamycin analog mTORC1 inhibitors. Anakuria’s lead Phase 1 ready program, AT-20494 provides Janssen with a first-in-class opportunity in autosomal dominant polycystic kidney disease, or ADPKD. This deal was facilitated by Johnson & Johnson Innovation.

Under the terms of the agreement, Janssen has acquired all outstanding shares of Anakuria, which is now a wholly owned subsidiary of Janssen.

The Goodwin team was led by Danielle Lauzon, Dan Hughes, Chris Guerin, and Will Ogden (Corporate); and included Kathleen Kean (Intellectual Property); Dan Karelitz and Leon Peschel (Tax); Sarah Bock (ERISA & Executive Compensation); Steven Tjoe (FDA); Paul Jin (Antitrust); and Caroline Galiatsos (Employment); with invaluable assistance from Coleen Doyle.

For more details, read the press release.